Whalesbook
Significant Tax Demands Issued
Akums Drugs and Pharmaceuticals Ltd., along with its subsidiary Akumentis Healthcare Ltd., have received tax assessment orders amounting to ₹133.75 crore. These demands, covering the period from April 1, 2018, to March 12, 2025, were issued by the Deputy Commissioner of Income Tax in New Delhi. Akums Drugs was assessed ₹60.09 crore, and Akumentis Healthcare was assessed ₹73.66 crore. The tax authorities based these assessments on disallowing various expenditures under Section 37(1) of the Income Tax Act, 1961.
Company Plans Appeal, Predicts No Major Financial Impact
Akums Drugs has indicated that an internal review suggests these tax orders will not materially affect its finances. The company believes the demands lack legal basis and intends to challenge them through formal appeals. This response is similar to reactions during a prior income tax search in January 2025, when the company stressed its cooperation and compliance with regulations, even as its stock price briefly fell.
Market Reaction and Company Valuation
Shares of Akums Drugs and Pharmaceuticals Ltd. closed down 1.29% on Wednesday, May 20, 2026, trading at ₹513.00, following the announcement of the tax demands. The company's market capitalization is approximately ₹8,100 crore. Its P/E ratio ranges between 26.4x and 73.3x, which appears competitive when compared to industry peers and the broader Asian Life Sciences average of 37.4x and 36.2x, respectively. For FY 2025-2026, the company reported revenue of ₹4,359 crore and a profit after tax of ₹256.4 crore, representing a 25% decrease from the prior year.
Regulatory Context and Past Incidents
The Indian pharmaceutical sector is governed by a stringent regulatory environment, including oversight from bodies like the Central Drugs Standard Control Organization (CDSCO). These regulations aim to ensure drug quality and safety but can create compliance challenges. The income tax search conducted in January 2025, which caused an approximate 6-7% stock price decline, demonstrated the market's sensitivity to tax and regulatory scrutiny. The current demands stem from the tax authorities' examination of the company's financial activities during the specified block period.